Geoffrey Gilmartin is taking on a new role at Proteostasis Therapeutics (NASDAQ: PTI) as its chief medical officer. He will succeed Po-Shun Lee, who will become a consultant to the Boston-based cystic fibrosis (CF) drug developer after serving in the CMO role for the past four years. Gilmartin joined Proteostasis in 2016 as chief development officer and has been its chief medical affairs officer since February. His experience also includes prior posts at AstraZeneca (NYSE: AZN) and Vertex Pharmaceuticals (NASDAQ: VRTX).
UNDERWRITERS AND PARTNERS